Oestrogen levels linked to risk of COVID-19 death in older women


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
It May be worth exploring hormone therapy to reduce infection severity, say, researchers

An older woman’s oestrogen levels may be linked to her chances of dying from COVID-19, with higher levels of the hormone seemingly protective against severe infection, suggests research published in the open access journal BMJ Open.

It may be worth exploring supplemental hormone treatment to curb the severity of COVID-19 infection in women who have already gone through the menopause, say the researchers.

Women seem to have a lower risk of severe COVID-19 infection than men, even after accounting for potentially influential factors. And this is also true of other serious recent viral infections, such as MERS (Middle East Respiratory Syndrome).

It has been suggested, therefore, that oestrogen may have a role in this gender discrepancy. To explore this further, the researchers compared the potential effects of boosting and reducing oestrogen levels on COVID-19 infection severity.

They drew on national data from the Swedish Public Health Agency (all those testing positive for SARS-CoV-2); Statistics Sweden (socioeconomic factors); and the National Board of Health and Welfare (causes of death).

In all, 49,853 women were diagnosed with COVID-19 between 4 February and 14 September 2020 in Sweden, 16,693 of whom were aged between 50 and 80. 

The study sample included 14,685 women in total: 227 (2%) had been previously diagnosed with breast cancer and were on oestrogen blocker drugs (adjuvant therapy) to curb the risk of cancer recurrence (group 1); and 2535 (17%) were taking hormone replacement therapy (HRT) to boost their oestrogen levels in a bid to relieve menopausal symptoms (group 2).

Some 11,923 (81%) women acted as the comparison group as they weren’t on any type of treatment, either to enhance or reduce their systemic oestrogen levels.

Analysis of all the data showed that compared with no oestrogen treatment, the crude odds of dying from COVID-19 were twice as high among women on oestrogen blockers (group 1), but 54% lower among women on HRT (group 2). 

After accounting for potentially influential factors, such as age, annual disposable income, educational attainment, and coexisting health conditions, the odds of dying from COVID-19 remained significantly lower (53%) for women on HRT (group 2).

Unsurprisingly, age was significantly associated with the risk of dying from COVID-19, with each extra year associated with 15% greater odds, while every additional coexisting condition increased the odds of death by 13%. 

And those with the lowest household incomes were nearly 3 times as likely to die as those with the highest.

This is an observational study, and as such, can’t establish cause. There were no data on the precise doses of HRT or oestrogen blocker drugs, or their duration, nor on weight or smoking, while the number of women in group 1 on adjuvant therapy was relatively small.

These factors may have been influential. But the researchers conclude: “This study shows an association between oestrogen levels and COVID-19 death. Consequently, drugs increasing oestrogen levels may have a role in therapeutic efforts to alleviate COVID-19 severity in postmenopausal women and could be studied in randomised control trials.”

Tags : #Oestrogen #OlderwomenCancer #Cancer #WomenCancer #BMJOpen

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026